

MAT Waiver Training April 22, 2022 8 AM – 12:30 PM PT

Location: Virtual Meeting

Tuition: No Cost

To register: <https://www.eventbrite.com/e/data-waiver-training-virtual-4222022-tickets-264378973627>



What is MAT Waiver Training?

The Providers Clinical Support System (PCSS) Half and Half Medications for Addiction Treatment (MAT) waiver training course provides an overview of buprenorphine, one of three medications approved by the FDA for the treatment of opioid use disorder (OUD). This course fulfills the 8 hour requirement for physicians, physician assistants (PAs) and Nurse Practitioners (NPs), Certified Nurse Midwives (CNMs), Clinical Nurse Specialists (CNSs), and Certified Registered Nurse Anesthetists (CRNAs) who are eligible to prescribe buprenorphine in office-based settings for the treatment of OUD. The course also provides an overview of prevention, identification, and treatment of substance use disorders emphasizing OUD. Residents may take the course and apply for their waiver once they obtain their DEA license.

The Half and Half Course

The training is provided in a “Half and Half” format, which means the first part is taken via virtual meeting and the second part, for physicians, PAs and NPs, CNMs, CNSs, and CRNAs is completed online. The Half and Half course is also open to interested practitioners who are involved in serving patients receiving medications for addiction treatment for OUD (counselors, social workers, pharmacists, etc.), as well as those who are eligible to apply for their waiver: physicians, PAs, and NPs, CNMs, CNSs, and CRNAs. Following the completion of the virtual training, an access link will be sent to participants for the online portion and eligible providers will be instructed regarding how they can apply for their waiver through the Substance Abuse and Mental Health Services Administration (SAMHSA). Eligible providers are encouraged to complete the course and apply to SAMHSA, and to make use of the [PCSS mentor program](#) and [discussion forum](#) for additional support.

American Academy of Addiction Psychiatry (AAAP) is the DATA 2000 Sponsor for this training.

Educational Objectives

- Screen and identify patients with OUD and define evidence-based treatments.
- Discuss the pharmacology of opioids as it relates to treatment of opioid use disorder (OUD) patients.
- Describe the fundamentals of office-based opioid treatment including the treatment of the co-morbid patient.
- Explain the process of buprenorphine induction as well as stabilization and maintenance.
- Discuss all FDA approved antagonist and agonist medications to treat OUD.
- Discuss basic office protocols including medical record documentation and confidentiality.
- Utilize evidence-based resources to ensure providers have the confidence to prescribe buprenorphine for patients with OUD.
- Recognize the importance of obtaining a waiver to begin treating patients with OUD.

PCSS has a comprehensive library of materials available at no cost, created to give providers confidence in preventing and treating these medical disorders. PCSS also provides a no-cost clinical coaching/mentoring program to help primary care providers in their ability to address these concerns. More info: <https://pcssnow.org/>.

CME Accreditation

Oregon Health & Science University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

OHSU School of Medicine designates this live activity for a maximum **4.25 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Physician/APP Participation in the Learning Process

Physician/APPs will only be awarded **4.5 AMA PRA Category 1 Credits™** after completing the “second” half of the training. To obtain a buprenorphine training certificate of completion you must complete BOTH halves of the training and receive a minimum cumulative score of 75% on the examination.

Disclosure of Support

Funding for this initiative was made possible (in part) by grant no. 1H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Partial funding for this program comes from SAMHSA to the Oregon Health Authority to expand MAT capacity across Oregon. Additional funding is also provided through OHSU and the Western States Node of the National Institute on Drug Abuse Clinical Trials Network.

Opportunity to participate in research;

As part of the support provided by SAMHSA, participants will have the opportunity to participate in research by filling out a survey at the end of the training session you participate in, and then completing a follow-up survey six months after the training is completed. An information sheet that describes these activities in detail will be provided to you at the training session or by e-mail before the session begins. The surveys will be used to help us understand perceptions of knowledge and confidence gains as a result of MAT training and its potential impact on the patients you provide MAT care for. All participants wishing to participate will be eligible. It is expected that the extra time needed to participate in the surveys will not exceed 10 min each.

For more information contact Philippe Thuillier thuillie@ohsu.edu (503-314-2218) or our program coordinator Marissa Fuqua Miller milmaris@ohsu.edu . This study is under the IRB protocol 20496.